Published in Blood on January 15, 1992
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res (2012) 1.46
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
All-trans-retinoic acid distribution and metabolism in vitamin A-marginal rats. Am J Physiol Gastrointest Liver Physiol (2006) 1.01
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med (2015) 0.99
Design and synthesis of (E)-1-((3-ethyl-2,4,4-trimethylcyclohex-2-enylidene)methyl-4-substituted benzenes from 1-(2,6,6-trimethylcyclohex-1-enyl)ethanol. Chem Commun (Camb) (2009) 0.98
Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer (2006) 0.95
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. EBioMedicine (2015) 0.94
Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Exp Cell Res (2014) 0.93
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. Br J Cancer (2007) 0.91
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer (2005) 0.90
Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Mol Pharmacol (2014) 0.90
Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J Pharmacol Exp Ther (2007) 0.90
Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK. PLoS One (2010) 0.89
Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase. Mol Pharmacol (2011) 0.89
Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity. Br J Cancer (2002) 0.88
The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br J Cancer (1998) 0.88
Induction of the oxidative catabolism of retinoid acid in MCF-7 cells. Br J Cancer (1997) 0.86
The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer (2016) 0.84
A phase 1 study of tazarotene in adults with advanced cancer. Br J Cancer (2003) 0.84
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. Curr Top Med Chem (2013) 0.82
Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines. Br J Cancer (1997) 0.82
Disseminated exfoliative dermatitis associated with all-transretinoic Acid in the treatment of acute promyelocytic leukemia. Case Rep Med (2012) 0.79
Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer (2007) 0.79
Pharmacokinetics of a novel agent, R667, in patients with emphysema. Br J Clin Pharmacol (2007) 0.78
Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer. Adv Pharmacol (2015) 0.76
Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways. Sci Rep (2017) 0.76
KN-62 analogues as potent differentiating agents of HL-60 cells. Leuk Res (2006) 0.76
Arachidonic acid-mediated cooxidation of all-trans-retinoic acid in microsomal fractions from human liver. Br J Pharmacol (2000) 0.75
Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions. J Pharmacol Exp Ther (2017) 0.75
Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling. J Cell Mol Med (2015) 0.75
All-trans retinoic acid-incorporated nanoparticles of deoxycholic acid-conjugated dextran for treatment of CT26 colorectal carcinoma cells. Int J Nanomedicine (2013) 0.75
Tretinoin overdose: a first case report. J Med Toxicol (2009) 0.75
Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. Sci Rep (2014) 0.75
Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancer. Am J Cancer Res (2015) 0.75
Oncology. Postgrad Med J (1993) 0.75
Study on cytochrome p-450 dependent retinoic Acid metabolism and its inhibitors as potential agents for cancer therapy. Sci Pharm (2011) 0.75
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem (2011) 0.75
Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells. Invest New Drugs (2010) 0.75
Pin1-Targeted Therapy for Systemic Lupus Erythematosus. Arthritis Rheumatol (2016) 0.75
Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A (1999) 39.79
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell (1994) 6.52
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med (1981) 4.90
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol (2001) 3.24
The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med (1992) 2.99
Corneal endothelial dystrophy. A study of 64 families. Arch Ophthalmol (1978) 2.88
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature (1986) 2.57
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 2.43
EXCHANGE REACTIONS OF DIIODOTYROSINE. Science (1944) 2.41
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med (1988) 2.40
Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem (1980) 2.38
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood (1993) 2.29
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008) 2.27
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood (1999) 2.22
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. J Natl Cancer Inst (1989) 2.19
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
All-trans-retinoic acid: what is it good for? J Clin Oncol (1992) 2.03
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res (1997) 2.03
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med (1981) 1.97
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother (1997) 1.88
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res (1999) 1.85
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene (2006) 1.79
Infection with human T-cell leukemia virus type I in patients with leukemia. N Engl J Med (1988) 1.78
Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol (1982) 1.75
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg (1992) 1.72
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood (1997) 1.69
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U. Antimicrob Agents Chemother (1984) 1.67
Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. J Biol Chem (1990) 1.65
Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. Cancer Res (1967) 1.60
Adenyl cyclase as a link between photon capture and changes in membrane permeability of frog photoreceptors. Proc Natl Acad Sci U S A (1971) 1.60
Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene (1999) 1.58
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood (1995) 1.58
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A (2000) 1.57
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst (1993) 1.56
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst (1991) 1.55
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res (1994) 1.54
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol (2008) 1.49
Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J Biol Chem (1979) 1.49
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med (1982) 1.47
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood (1992) 1.46
Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer (1994) 1.45
CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest (1999) 1.45
Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med (1992) 1.43
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med (1999) 1.42
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. Blood (1993) 1.41
Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant (2004) 1.41
Restraining the violent pregnant patient. Am J Psychiatry (1991) 1.38
Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother (1999) 1.38
Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem (1999) 1.36
Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J Biol Chem (1979) 1.35
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother (1994) 1.33
Hydroxyurea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res (1967) 1.32
Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis (2005) 1.32
Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A (1996) 1.31
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol (1985) 1.31
Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry (1995) 1.29
Insulinopenic diabetes after rodenticide (Vacor) ingestion: a unique model of acquired diabetes in man. Diabetes (1980) 1.29
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res (1995) 1.29
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 1.29
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood (2001) 1.27
Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res (1992) 1.26
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 1.23
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood (2000) 1.23
Cyclic GMP injected into retinal rod outer segments increases latency and amplitude of response to illumination. Proc Natl Acad Sci U S A (1978) 1.21